Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Part D Formulary Coverage & PA | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCommunity-CarePolicy N/A

    Senior Health Plan 2026 Formulary — Part D Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the prescription drugs covered, coverage rules (prior authorization, step therapy, quantity limits), and cost-sharing tiers for Senior Health Plan members of Platinum, Platinum Plus, Silver Plus, and Oklahoma Dual Complete. Applies to plan members and network pharmacies using the 2026 formulary table.

    Policy Summary
    PayerCommunity-Care
    PolicySenior Health Plan 2026 Formulary — Part D Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date02/18/2026
    Last ReviewFeb 18, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA/PA_NSO) and document quantity limits (QL) when submitting claims for listed drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    02/18/2026formulary last updated
    Monthlyformulary updates posted
    72/24hexception decision timelines
    30 daysnotice before mid-year member changes
    4plan variants shown

    Formulary Coverage & Temporary Supply

    General formulary coverage

    Covered when ALL of the following are met

    Formulary coverage general: Drug is listed on the Senior Health Plan formulary; the drug is medically necessary for the member; the prescription is filled at a plan network pharmacy; and other applicable plan rules (for example, prior authorization, quantity limits, or step therapy) are followed.

    Standard Part D coverage conditions; see formulary for drug‑specific REQUIREMENTS/LIMITS.

    Temporary supply / transition policy

    Temporary supply coverage rules

    Transition and emergency supplies: When a drug is not on the formulary or is subject to a coverage restriction, the plan will cover a temporary supply while the member and prescriber pursue an exception or alternative therapy.30 days

    New or continuing members: up to a 30‑day temporary supply. Long‑term care residents: up to a 31‑day emergency supply. Allows time to request a formulary exception or switch therapy.

    Policy Summary
    PayerCommunity-Care
    PolicySenior Health Plan 2026 Formulary — Part D Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date02/18/2026
    Last ReviewFeb 18, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA/PA_NSO) and document quantity limits (QL) when submitting claims for listed drugs.
    SourceLink
    On This Page
    Formulary Coverage & Temporary SupplyFormulary Flags, Codes & Quantity Limits (Coding)Prior Authorization, Step Therapy & Documentation RequirementsStep Therapy Indicators & Class-Level RulesQuantity Limits (QL) per Drug ExampleSite of Care & Dispensing NotesTable Abbreviations & LegendPolicy Background & ScopeDocument Updates & Review Dates
    Setting change support: If a member experiences a change in setting of care (for example, discharge or admission to long‑term care), the physician or pharmacy may request a temporary supply to cover the transition period.30 days

    Temporary supply permits refills to provide up to a 30‑day supply when prescription quantity is written for fewer days.

    Formulary coverage entries (table-driven)

    Coverage and utilization management as listed in the formulary table for each product

    Formulary entry model: Each product line in the formulary identifies the drug name, strength/formulation, DRUG TIER, and a REQUIREMENTS/LIMITS field. Entries may include flags such as PA, PA_NSO, PA_BvD, ST or ST_NSO and quantity limits (QL).

    Clinical eligibility criteria are not provided in the table excerpt; use REQUIREMENTS/LIMITS to determine utilization controls and follow plan PA/step procedures.

    PA and QL indicators: Products marked PA_NSO require prior authorization (non‑standard/special handling) and many product lines include quantity limits expressed as QL= /.

    See table header for symbol definitions and last updated date (03/01/2026).

    Formulary coverage by drug entry

    Drugs shown are on the Part D formulary with the listed drug tier and any associated requirement/limit codes.

    Formulary entries: Each listed product (drug + specific strength/formulation) is included on the formulary with a DRUG TIER assignment and, when present, REQUIREMENTS/LIMITS codes such as PA_NSO, PA, ST_NSO, PA_BvD, INS and quantity limits (QL).

    Coverage for the product is subject to the listed requirement/limit codes; obtain prior authorization where indicated and adhere to QL values.

    Examples: Example entries include starter kits flagged PA_NSO QL=56 EA/28 Days; lurasidone strengths with QL=30 EA/30 Days; VRAYLAR products with PA_NSO QL=30 EA/30 Days; long‑acting injectables with NDS QL expressed in mL per period; clozapine formulations with specific QL values.

    Use the formulary row for the precise tier and REQUIREMENTS/LIMITS when processing coverage requests or claims.

    Formulary coverage lines

    Coverage and utilization limits are defined per drug line as Tier assignment and REQUIREMENTS/LIMITS entries

    Formulary line items: Each drug line includes the drug name and formulation, a DRUG TIER assignment, and a REQUIREMENTS/LIMITS field which may specify quantity limits (QL), prior authorization flags (PA, PA_NSO, PA_BvD), step therapy (ST, ST_NSO), insulin designations (INS), or NDS unit‑dose statements.

    Follow the REQUIREMENTS/LIMITS value to determine necessary provider actions (PA submission, documentation, adherence to QL) for coverage.

    Processing guidance: When a REQUIREMENTS/LIMITS entry shows PA or PA_NSO, obtain prior authorization before dispensing; when QL is shown (for example QL=30 EA/30 Days or QL=960 ML/30 Days), the dispensing pharmacy must adhere to that limit when filling refills within the stated period.

    Documentation supporting PA or dosage (for BvD or NDS entries) should be submitted per plan instructions.

    Drugs that are withdrawn from sale by the manufacturer or removed by the FDA for safety or effectiveness reasons may be immediately removed from the formulary and will not be covered. When other formulary changes are made (for example adding a generic or biosimilar, moving a drug to a different tier, or adding utilization controls), the plan will normally provide at least 30 days' notice to affected members before the change is effective, or supply a one-time 30-day refill when a member requests a refill. Members and prescribers may request a formulary exception to continue coverage of a drug affected by such changes; the notice to members will include information on how to request an exception.

    The excerpted formulary pages show many product-level entries with DRUG TIER and REQUIREMENTS/LIMITS fields (examples include biologic injectables with NDS PA and QL entries), but there are no categorical or blanket exclusions listed in these chunks. Coverage for each listed product is determined by its line entry (tier plus any requirement codes such as PA, NDS PA, PA_NSO, or QL) rather than by an explicit exclusion statement.

    Within the provided extract there are no statements that explicitly exclude classes of drugs or specific products from coverage. The table rows include normal formulary annotations (tier, PA_NSO, PA, QL) that indicate utilization controls; these are not presented in the source as categorical exclusions in this excerpt.

    No statements describing drugs as "not medically necessary" (NMN) are present in the supplied excerpt. The document segment focuses on formulary listings, tiers, and requirements/limits rather than explicit NMN determinations.

    Formulary Flags, Codes & Quantity Limits (Coding)

    Formulary flags and quantity limitsmixed
    QL=480 ML/30 DaysQty limit for an oral suspension (example from excerpt)
    QL=60 EA/30 DaysQty limit for tablets (example from excerpt)
    PA_NSOPrior authorization (non-standard) flag
    Formulary requirement codesmixed
    PA_NSOPrior authorization, non-standard or specialty
    PAPrior authorization
    ST_NSOStep therapy, non-standard or specialty
    STStep therapy
    QLQuantity limit (followed by numeric limits in product lines)
    INSInsulin designation/coverage flag
    PA_BvDPrior authorization with billing/verification descriptor (as used for FIASP inj)
    NDS PANon-standard dispensing/site prior authorization (appears for mifepristone)
    Representative drug lines (partial list)mixed
    citalopram 10mgcitalopram 10mg tab — tier 1
    escitalopram 10mgescitalopram 10mg tab — tier 1
    fluoxetine 10mgfluoxetine 10mg cap — tier 1
    paroxetine 20mgparoxetine 20mg tab — tier 1
    sertraline 50mgsertraline 50mg tab — tier 1
    EXXUA 18.2mg/36.3mg/54.5mg/72.6mg EREXXUA ER tablets — tier 4, PA_NSO QL=30 EA/30 Days
    TRINTELLIX 5/10/20mgTRINTELLIX — tier 3, ST_NSO QL=30 EA/30 Days
    FETZIMA 20/40/80/120mg ERFETZIMA — tier 4, PA_NSO QL=30 EA/30 Days
    desvenlafaxine 25/50/100mg ERdesvenlafaxine succinate ER — tier 2, QL=30 EA/30 Days
    DRIZALMA 20/30/40/60mgDRIZALMA DR sprinkle caps — tier 4, PA_NSO QL=60 EA/30 Days
    1–10 of 15
    1/2
    Selected GLP-1 agentsNDC-like/textCovered
    OZEMPIC 4MG/3ML PEN INJDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=3 ML/28 Days
    OZEMPIC 8MG/3ML PEN INJDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=3 ML/28 Days
    RYBELSUS 14MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days
    RYBELSUS 3MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days
    RYBELSUS 7MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days
    TRULICITY 0.75MG/0.5ML AUTO-INJECTORDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    TRULICITY 1.5MG/0.5ML AUTO-INJECTORDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    TRULICITY 3MG/0.5ML AUTO-INJECTORDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    TRULICITY 4.5MG/0.5ML AUTO-INJECTORDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    Insulin products and related formulary entriesNDC-like/textCovered
    FIASP 100UNIT/ML CARTRIDGEDRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    FIASP 100UNIT/ML INJDRUG TIER = 3; REQUIREMENTS/LIMITS = INS PA_BvD
    FIASP 100UNIT/ML PEN INJ (3ML)DRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMALOG 100UNIT/ML CARTRIDGEDRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMALOG 100UNIT/ML KWIKPEN (3ML)DRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMALOG 200UNIT/ML KWIKPEN (3ML)DRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMALOG JUNIOR 100UNIT/ML PEN INJ (3ML)DRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMULIN (70/30) 100UNIT/ML PEN INJ (3ML)DRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMULIN N 100UNIT/ML INJDRUG TIER = 3; REQUIREMENTS/LIMITS = INS
    HUMULIN R 500UNIT/ML INJDRUG TIER = 3; REQUIREMENTS/LIMITS = INS PA_BvD
    1–10 of 14
    1/2
    SGLT2s, PCSK9 and selected QL entriesNDC-like/textCovered
    DAPAGLIFLOZIN 10MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    FARXIGA 10MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    JARDIANCE 10MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    REPATHA 140MG/ML AUTO-INJECTORDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    REPATHA 140MG/ML SYRINGEDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=2 ML/28 Days
    Miscellaneous agents (antidiarrheals, opioid antagonists, antiemetics, antifungals)NDC-like/textCovered
    alosetron 0.5MG TABDRUG TIER = 2; REQUIREMENTS/LIMITS = QL=60 EA/30 Days
    KLOXXADO 8MG/0.1ML NASAL SPRAYDRUG TIER = 3; REQUIREMENTS/LIMITS = .
    naloxone 0.4MG/ML CARTRIDGEDRUG TIER = 2; REQUIREMENTS/LIMITS = .
    ondansetron 0.8MG/ML ORAL SOLNDRUG TIER = 2; REQUIREMENTS/LIMITS = PA_BvD QL=900 ML/30 Days
    aprepitant 125MG CAPDRUG TIER = 2; REQUIREMENTS/LIMITS = PA_BvD QL=3 EA/2 Days
    CRESEMBA 186MG CAPDRUG TIER = 5; REQUIREMENTS/LIMITS = NDS PA
    fluconazole 100MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    Antifungals and antihyperlipidemics examplesNDC-like/textCovered
    posaconazole 100MG DR TABDRUG TIER = 2; REQUIREMENTS/LIMITS = PA QL=96 EA/30 Days
    voriconazole 200MG TABDRUG TIER = 2; REQUIREMENTS/LIMITS = PA QL=120 EA/30 Days
    ezetimibe 10MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = QL=30 EA/30 Days
    NEXLETOL 180MG TABDRUG TIER = 3; REQUIREMENTS/LIMITS = PA QL=30 EA/30 Days
    atorvastatin 10MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    Fibrate and statin examplesNDC-like/textCovered
    fenofibrate 134MG CAPDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    gemfibrozil 600MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    rosuvastatin calcium 10MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    simvastatin 10MG TABDRUG TIER = 1; REQUIREMENTS/LIMITS = .
    Quantity limits and PA markers from formularymixed
    QL=30 EA/30 DaysQuantity limit: 30 each per 30 days
    QL=60 EA/30 DaysQuantity limit: 60 each per 30 days
    QL=120 EA/30 DaysQuantity limit: 120 each per 30 days
    QL=300 ML/30 DaysQuantity limit: 300 milliliters per 30 days
    NDS PANon-standard/needs prior authorization
    Formulary requirement labelsmixed
    PA QL=20 EA/10 DaysPrior authorization and quantity limit for DIFICID 200MG TAB / fidaxomicin
    QL=1800 ML/30 DaysQuantity limit for linezolid 100mg/5ml oral suspension
    QL=60 EA/30 DaysQuantity limit for linezolid 600mg tab
    Antineoplastic utilization codesmixed
    PA_NSO QL=30 EA/30 DaysPrior authorization / special handling and quantity limit for erlotinib formulations
    NDS PA_NSO QL=60 EA/30 DaysNon-standard dispensing with prior auth and QL for gefitinib / GILOTRIF etc.
    Example QL codes (from chunk examples)mixed
    QL=1 EA/168 DaysTRELSTAR 22.5MG INJ quantity limit
    QL=1 EA/28 DaysTRELSTAR 3.75MG INJ quantity limit
    QL=120 EA/30 DaysXTANDI 40MG cap/tab quantity limit
    QL=60 EA/30 DaysXTANDI 80MG tab quantity limit
    Additional QL examplesmixed
    QL=240 EA/30 DaysALECENSA 150MG CAP quantity limit
    QL=30 EA/30 DaysALUNBRIG 180MG TAB quantity limit
    QL=90 EA/30 DaysRUBRACA 200MG tab alternative QL
    Formulary requirement/limit codesmixed
    QL=28 EA/28 DaysQuantity limit 28 each per 28 days (example format appearing throughout document)
    QL=120 EA/30 DaysQuantity limit 120 each per 30 days
    PA_NSOPrior authorization / Notification status flag used in table
    NDS PA_NSOTable notation combining NDS and PA_NSO flag as listed
    Formulary quantity limit codes and unit-dose statementsmixed
    NDS QL=.75 ML/28 DaysINVEGA SUSTENNA 117MG/0.75ML syringe quantity limit
    NDS QL=1 ML/28 DaysINVEGA SUSTENNA 156MG/ML syringe quantity limit
    NDS QL=1.50 ML/28 DaysINVEGA SUSTENNA 234MG/1.5ML syringe quantity limit
    QL=.25 ML/28 DaysINVEGA SUSTENNA 39MG/0.25ML syringe quantity limit
    NDS QL=.50 ML/28 DaysINVEGA SUSTENNA 78MG/0.5ML syringe quantity limit
    NDS QL=1 EA/28 DaysABILIFY MAINTENA quantity limit
    QL=3.90 ML/56 DaysARISTADA 1064MG quantity limit
    NDS QL=1.60 ML/28 DaysARISTADA 441MG quantity limit
    NDS QL=2.40 ML/28 DaysARISTADA 662MG quantity limit
    QL=2.40 ML/42 DaysARISTADA 675MG quantity limit
    1–10 of 11
    1/2
    Quantity limit examples
    ketorolac tromethamine 10 mg tabletQL=20 EA/5 Days
    nabumetone 500 mg tabletQL=120 EA/30 Days
    fentanyl transdermal patches (various mcg/hr strengths)QL=10 EA/30 Days
    Quantity limits (exact values shown)
    example liquid injectable/solution QLQL=8 ML/28 Days
    example unit-dose QLQL=3 EA/28 Days
    common tablet QLQL=60 EA/30 Days
    Sample quantity limits
    sample tablet quantity limitQL=60 EA/30 Days
    sample oral suspension quantity limitQL=360 ML/30 Days
    sample patch/tablet QLQL=10 EA/30 Days
    Quantity limits shown as QL (examples)
    citalopram 2 mg/mL oral solutionQL=600 ML/30 Days
    many tablet presentations (example)QL=30 EA/30 Days
    some GLP-1 injectables (unit-volume limits)QL=2 ML/28 Days
    Repatha volume limit
    REPATHA 140 mg/mL (auto-injector/syringe)QL=2 ML/28 Days
    NoteREPATHA entries also include PA requirement as shown in the Requirements/Limits column
    source rowsSee formulary REPATHA lines for exact PA + QL wording
    Ozempic volume limit
    OZEMPIC (2/4/8 mg pens) 3 mL presentationsQL=3 ML/28 Days
    OZEMPIC 4 mg/3 mL and 8 mg/3 mL pensListed with PA QL=3 ML/28 Days
    OZEMPIC formulary rowsSee OZEMPIC lines in incretin/GLP-1 section for full requirements
    Oral GLP-1 or SGLT2 tablet quantity
    Oral GLP-1 or SGLT2 tablets (examples)QL=30 EA/30 Days
    RYBELSUS 3/7/14 mg tabletsQL=30 EA/30 Days
    SGLT2 inhibitors (dapagliflozin, farxiga, jardiance)QL=30 EA/30 Days
    Quantity limits (examples)
    common 30-day tablet QLQL=30 EA/30 Days
    larger 30-day tablet QLQL=60 EA/30 Days
    extended 30-day tablet QLQL=120 EA/30 Days
    Common dispensing period
    Typical dispensing period noted in tableEA/28 Days or EA/30 Days (28–30 days common)
    Examples use either 28- or 30-day windowsMany QL entries are expressed per 28 Days or per 30 Days
    Pharmacy actionDispensing must adhere to the QL time window shown for each product
    Quantity Limit examples (exact values)
    example mid-range tablet QLQL=60 EA/30 Days
    example larger tablet QLQL=240 EA/30 Days
    noteExact QL values appear per product line in the formulary table
    Quantity limit examples (mixed)
    common tablet QL examplesQL=30 EA/30 Days; QL=60 EA/30 Days
    short-interval QL exampleQL=2 EA/28 Days (some LAI/microsphere injectables)
    large-volume oral solution exampleQL=600 ML/30 Days
    Quantity limits (table examples)
    Example QL per 30 daysQL=30 EA/30 Days
    Higher QL exampleQL=120 EA/30 Days
    Large-volume exampleQL=960 ML/30 Days

    Prior Authorization, Step Therapy & Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Our plan requires prior authorization (PA) for many listed drugs. Providers and members must obtain approval from Community-Care before dispensing or filling prescriptions for drugs marked with PA, PA_NSO, NDS PA, PA_BvD, PA_NSO, or similar flags in the formulary. Failure to obtain required prior authorization may result in the plan denying payment for the drug.

    • PA (Prior Authorization) required for many agents; PA_NSO indicates prior authorization required for new starts only.
    • NDS PA / NDS flags indicate non-extended day supply and often require PA and limit dispensing to 1-month supplies.
    • PA_BvD indicates a Part B vs Part D determination is required; submit clinical setting/use to determine correct benefit.
    • PA_NSO and NDS PA_NSO flags are common on specialty and oncology agents; these typically require prior authorization and/or provider notification before coverage.
    • Failure to obtain required PA may result in claim denial or non-coverage.
    Prior Authorization

    PA and Quantity Limits for Selected Drugs

    Selected drug categories and specific products are subject to PA and/or quantity limits (QL). Specialty biologics, oncology agents, GLP-1 agonists/weight-loss agents, PCSK9 inhibitors, certain topical testosterone products, anthelmintics, and many high-cost antivirals/hepatitis therapies explicitly list PA and QL values in the formulary.

    • Specialty biologics (e.g., DUPIXENT, FASENRA, NUCALA, XOLAIR, COSENTYX, TREMFYA, SKYRIZI) show PA or NDS PA and defined quantity limits (mL or EA per 28/30/365 days).
    • GLP-1 agents (e.g., MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) are marked PA with specific QL (mL or EA per period).
    • PCSK9 inhibitors (Repatha) require PA and have volume-based QL (e.g., PA QL=2 ML/28 Days).
    • Topical testosterone products require PA with gram-based QL (e.g., PA QL=300 GM/30 Days).
    • Anthelmintics: ivermectin 3mg tab requires PA and QL=30 EA/90 Days; albendazole has an annual QL.
    Prior Authorization

    PA_NSO / NDS PA_NSO Requirement (New Starts / Non-Standard Dispensing)

    Drugs marked with PA_NSO or NDS PA_NSO require additional action on initiation or for non-standard dispensing. Oncology and specialty oral/injectable agents frequently carry NDS PA_NSO indicators; prescribers must obtain PA before the first fill and adhere to any quantity limits shown.

    • NDS PA_NSO often appears on anticancer agents, antineoplastics, and some high-cost specialty oral therapies — obtain PA prior to initiation.
    • Quantity limits for NDS items may be expressed as EA or mL per 28/30/365 days and must be followed.
    • Examples: multiple antineoplastic agents and initiation packs list NDS PA_NSO with explicit QL values.
    Billing Rule

    Insulin PA / Insulin-Specific Requirements

    Insulin products have insulin-specific coverage indicators (INS) and some insulin formulations require PA_BvD for Part B vs Part D determination. For insulins marked INS or INS PA_BvD, submit information about intended use/setting as needed and follow insulin program rules (pricing caps may apply).

    • Many insulins are labeled INS (covered under insulin program) — check formulary row for INS or INS PA_BvD.
    • If PA_BvD is indicated, provide clinical/use setting details to determine Medicare Part B vs Part D coverage before dispensing.
    • Examples: FIASP, HUMULIN R 500UNIT/ML, INSULIN LISPRO, LYUMJEV show INS or INS PA_BvD flags.
    Documentation Required

    Specialty Biologic Prior Authorization & Dose/Unit Documentation

    Specialty biologics and long-acting injectables require dose/unit documentation and adherence to mL-based quantity limits. Pharmacies and prescribers must submit documentation of dosing schedule, unit volume, and justification when requesting authorization for these agents.

    • Formulary rows for biologic injectables specify QL as mL per 28/30/365 days (e.g., DUPIXENT, XOLAIR, TREMFYA, SKYRIZI).
    • Dose/unit documentation supports PA requests and ensures dispensing adheres to mL-based limits.
    • Long-acting injectables (e.g., depot antipsychotics) may include NDS unit-volume limits — provide administration schedule and unit-dose details with PA.
    Documentation Required

    Documentation & Submission Requirements for PA / Exceptions

    When a formulary row displays REQUIREMENTS/LIMITS (PA, QL, ST, NDS, etc.), use those entries as the required documentation checklist when submitting authorizations or prior-notifications. Submit prescriber's supporting statement for formulary exceptions; plan generally decides within 72 hours (or 24 hours for expedited requests).

    • Include the formulary REQUIREMENTS/LIMITS code(s) and any quantity (QL) values in the PA submission.
    • Prescriber's supporting statement is required for formulary exception determinations; normal response time = 72 hours, expedited = 24 hours when indicated.
    • Follow abbreviation guidance at the beginning of the formulary when preparing documentation.
    Denial Risk

    Quantity Limits, Enforcement & Denial Risk

    Claims may be denied if prior authorization is not obtained or if dispensed quantities exceed stated QL values. Pharmacies must adhere to QL when filling refills, and prescribers should include QL rationale in PA requests.

    • Quantity limit exceedances can trigger denials — examples include linezolid 600mg tab QL=60 EA/30 Days, DIFICID PA QL=20 EA/10 Days, Repatha PA QL=2 ML/28 Days.
    • If a prescription exceeds a QL, submit clinical justification with the PA request or seek an exception.
    • Pharmacies must follow QL when dispensing partial supplies or mail-order quantities (NDS items limited to 1-month supply).
    Step Therapy

    Step Therapy: Limited/No Explicit Sequences in Excerpt

    Step therapy rules are noted where applicable (e.g., ST_NSO for TRINTELLIX). This formulary excerpt contains few explicit step-therapy sequences; where ST or ST_NSO appears, follow the step requirements or request an exception with prescriber's supporting statement.

    • TRINTELLIX entries include ST_NSO — step therapy applies for new starts only.
    • Most sections in this excerpt do not contain explicit step-by-step algorithms; treat ST flags as indicating a program requirement rather than a detailed sequence.
    • Providers may request exceptions if step therapy would cause harm or be ineffective for the member.
    Note

    Interpretation Guidance: Formulary Flags and Abbreviations

    Follow the formulary abbreviation guidance when interpreting flags: PA, QL, ST, NDS, PA_NSO, PA_BvD, ST_NSO, INS, VAC. Use the Requirements/Limits column values as the operational rules for coverage and for preparing PA or exception requests.

    • PA_BvD requires submission of use/setting info for Part B vs Part D determination.
    • NDS indicates non-extended day supply — limited to 1-month for retail and mail order; check QL values.
    • When in doubt, reference the formulary legend at the start of the drug table for symbol definitions.

    Step Therapy Indicators & Class-Level Rules

    Coverage labelSummary
    ST / ST_NSO
    Members must try specified preferred drugs before coverage of some non-preferred drugs. ST_NSO (Step Therapy for New Starts Only) applies to drugs newly started by a member; the member must try the required alternative(s) first or obtain an exception prior to coverage.
    Coverage labelInterpretation
    Class-level REQUIREMENTS/LIMITS
    Some therapeutic classes display 'REQUIREMENTS/LIMITS' at the class header which suggests program‑level rules or step edits may apply (for example ADHD and amphetamine class headers). Specific per‑drug step sequences are not detailed in this excerpt and would be defined elsewhere in the formulary or plan policy.
    Coverage labelNote
    Biologics / Specialty injectables
    No explicit step therapy steps for listed biologics are shown in these chunks. Biologic lines are annotated with prior authorization and non‑standard dosing/dispensing flags (e.g., NDS PA, NDS PA QL values) indicating PA and quantity limits govern coverage rather than step sequencing in this excerpt.
    Coverage labelSummary
    Step therapy absent
    No explicit step therapy sequences are listed in the provided chunks; prior authorization (PA), PA_BvD, PA_NSO, and quantity limits (QL) are the primary utilization controls shown.
    Coverage labelImplication for providers
    PA_NSO
    PA_NSO indicates a prior authorization requirement (often for specialty products) that applies to new starts; while it implies a clinical review or approval is required before coverage, no step therapy sequences are provided in these chunks.
    DrugStep therapy flag / Note
    TRINTELLIX (5mg, 10mg, 20mg)
    Marked ST_NSO with QL=30 EA/30 Days — indicates step therapy for new starts only (ST_NSO). Providers should obtain prior approval or document trial of preferred agents for new starts per plan rules.
    Coverage labelEffect on coverage
    PA_BvD
    PA_BvD appears on several antiemetic/supportive care agents (e.g., ondansetron, aprepitant) indicating a prior authorization/benefit determination is required — implying clinical review prior to approval rather than an explicit step sequence.
    DrugRequirement
    metyrosine 250mg cap
    Listed with NDS PA — requires prior authorization before coverage. No step therapy sequence is specified in the excerpt.
    Coverage labelComment
    Antineoplastic agents with NDS PA_NSO
    Several high‑tier antineoplastic agents are annotated NDS PA_NSO (non‑standard dispensing / prior authorization/notification) and have quantity limits; these flags indicate special authorization/dispensing requirements prior to coverage rather than explicit step therapy sequences.
    Coverage labelInterpretation
    Requirement codes (PA / NDS / NSO)
    Products flagged with PA, NDS, NSO, PA_NSO, or similar codes may imply plan‑level utilization management or step requirements, but explicit step/failure sequences are not present in these chunks and would be defined in the plan’s PA/step policy documentation.
    ExampleNotes
    aripiprazole ODT (example lines)
    Flagged PA_NSO with QL=60 EA/30 Days in the formulary — demonstrates a prior authorization/quantity limit requirement on an oral product. No step sequencing logic is provided in the excerpt.

    Quantity Limits (QL) per Drug Example

    Site of Care & Dispensing Notes

    Note

    Table Abbreviations & Legend

    Policy Background & Scope

    This document is the Senior Health Plan Medicare Part D formulary for 2026. It lists covered prescription drugs organized by therapeutic class and by individual drug strength/formulation, shows the drug tier assignment for each line, and records plan-level utilization controls such as Prior Authorization (PA), specialty prior authorization markers (e.g., NDS PA, PA_NSO), step therapy flags (e.g., ST_NSO), and Quantity Limits (QL) expressed as an amount per time period (for example, QL=30 EA/30 Days or QL=3 ML/28 Days). The formulary also explains that biosimilars and interchangeable products may be managed per plan and state rules, and directs prescribers and pharmacies to follow the REQUIREMENTS/LIMITS entries when submitting prior authorization requests or claims.

    Note

    Document Updates & Review Dates

    2026-02-18last_review

    Policy last reviewed on 2026-02-18 as recorded in the document metadata.

    2026-03-01document_update

    Formulary pages show a 'Last Updated Date: 03/01/2026' timestamp on multiple table pages indicating content updates posted on 03/01/2026.

    2026-03-01table_update

    Formulary table sections include 'Last Updated Date: 03/01/2026' (repeated on several pages), reflecting a table-level update posted 03/01/2026.

    2026-03-01document_updateLatest

    Document footer and multiple content sections display 'Last Updated Date: 03/01/2026', indicating the document was updated on 03/01/2026.